Phio Pharmaceuticals (PHIO) Projected to Post Quarterly Earnings on Monday

Phio Pharmaceuticals (NASDAQ:PHIO) will likely be posting its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Phio Pharmaceuticals to post earnings of ($0.34) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its earnings results on Thursday, March 5th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.19. On average, analysts expect Phio Pharmaceuticals to post $-9 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Phio Pharmaceuticals Stock Performance

Shares of Phio Pharmaceuticals stock opened at $1.26 on Friday. The company has a fifty day moving average price of $1.14 and a 200 day moving average price of $1.47. Phio Pharmaceuticals has a twelve month low of $0.81 and a twelve month high of $4.19. The stock has a market cap of $14.64 million, a price-to-earnings ratio of -0.87 and a beta of 0.90.

Analysts Set New Price Targets

PHIO has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Phio Pharmaceuticals in a report on Tuesday, February 10th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $14.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Cetera Investment Advisers boosted its holdings in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 26.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 42,500 shares of the company’s stock after purchasing an additional 9,000 shares during the quarter. Cetera Investment Advisers owned approximately 0.39% of Phio Pharmaceuticals worth $45,000 at the end of the most recent quarter. Institutional investors own 57.31% of the company’s stock.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.